Full Text
P42 Budget Impact Analysis of Eculizumab Biosimilar for Treatment of Paroxysmal Nocturnal Hemoglobinuria from Public Hospital Perspective in 2023

Abstract

Authors

P. Robin A. De Coucy C. Hadjadj Petiteau. Moreau F

Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×